For the year ending 2025-12-31, ANIP made $883,366K in revenue. $77,180K in net income. Net profit margin of 8.74%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Net revenues | 883,366 | 614,376 | ||
| Cost of sales (excluding depreciation and amortization) | 341,310 | 250,210 | ||
| Research and development | 51,664 | 44,581 | ||
| Selling, general, and administrative | 317,745 | 249,636 | ||
| Gain on sale of building | - | 5,347 | ||
| Depreciation and amortization | 91,417 | 67,731 | ||
| Contingent consideration fair value adjustment | -31,012 | -619 | ||
| Loss (gain) on disposal of assets | -382 | - | ||
| Restructuring activities | 0 | - | ||
| Intangible asset impairment charge | 767 | 7,600 | ||
| Total operating expenses, net | 772,273 | 613,792 | ||
| Operating income | 111,093 | 584 | ||
| Unrealized gain on investment in equity securities | 2,824 | 6,307 | ||
| Interest expense, net | -20,060 | -17,602 | ||
| Other income (expense), net | 1,934 | -4,033 | ||
| Loss on extinguishment of debt | 0 | -7,468 | ||
| Income (loss) before expense (benefit) for income taxes | 95,791 | -22,212 | ||
| Income tax expense (benefit) | 17,454 | -3,690 | ||
| Net income (loss) | 78,337 | -18,522 | ||
| Dividends on series a convertible preferred stock | 1,157 | 1,625 | ||
| Net income (loss) available to common shareholders | 77,180 | -20,147 | ||
| Basic EPS | 3.5 | -1.04 | ||
| Diluted EPS | 3.32 | -1.04 | ||
| Basic Average Shares | 20,053,000 | 19,318,000 | ||
| Diluted Average Shares | 21,228,000 | 19,318,000 | ||
ANI PHARMACEUTICALS INC (ANIP)
ANI PHARMACEUTICALS INC (ANIP)